A pivotal study of CPI-613 in Acute Myeloid Leukemia (AML)

Trial Profile

A pivotal study of CPI-613 in Acute Myeloid Leukemia (AML)

Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs CPI 613 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 Jun 2017 According to a Rafael Pharmaceuticals media release, clinical development strategy for this trial will be presented at the 2017 BIO International Convention.
    • 27 Mar 2017 New trial record
    • 23 Mar 2017 According to a Cornerstone Pharmaceuticals media release, the company has received an approval from the U.S. Food and Drug Administration (FDA) to initiate this study. The FDA has provided a feedback to inform a trial design.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top